EyePoint (EYPT) Assets (2011 - 2026)
EyePoint (EYPT) posted Assets of $288.2 million for Q1 2026, down 20.82% sequentially from $364.0 million in Q4 2025, and down 20.51% YoY from $362.6 million in Q1 2025.
EyePoint (EYPT) Assets (2011 - 2026) Analysis & Trends
EyePoint has reported Assets for 16 years, with the latest figure at $288.2 million in Q1 2026.
- Quarterly Assets fell 20.51% year-over-year to $288.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $288.2 million (down 20.51% YoY) and the FY2025 annual result came in at $364.0 million, down 13.02% from the prior year.
- Assets fell to $288.2 million in Q1 2026 per EYPT's latest filing, from $364.0 million in the prior quarter.
- Over five years, Assets peaked at $418.5 million in Q4 2024 and troughed at $154.6 million in Q1 2023.
- A 5-year average of $274.4 million and a median of $288.2 million in 2026 frame the typical range for Assets.
- The sharpest annual moves came in 2023 and 2024: Assets tumbled 36.79% in 2023, then soared 112.98% in 2024.
- Over 5 years, Assets stood at $180.4 million in 2022, then jumped by 96.93% to $355.2 million in 2023, then climbed by 17.82% to $418.5 million in 2024, then retreated by 13.02% to $364.0 million in 2025, then declined by 20.82% to $288.2 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $288.2 million, $364.0 million, and $251.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 228.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 228.19 Mn |
| Mar 31, 2026 | 288.22 Mn |
| Dec 31, 2025 | 364.00 Mn |
| Sep 30, 2025 | 251.70 Mn |
| Jun 30, 2025 | 301.15 Mn |
| Mar 31, 2025 | 362.56 Mn |
| Dec 31, 2024 | 418.47 Mn |
| Sep 30, 2024 | 300.92 Mn |
| Jun 30, 2024 | 324.25 Mn |
| Mar 31, 2024 | 329.25 Mn |
| Dec 31, 2023 | 355.18 Mn |
| Sep 30, 2023 | 160.04 Mn |
| Jun 30, 2023 | 175.66 Mn |
| Mar 31, 2023 | 154.59 Mn |
| Dec 31, 2022 | 180.36 Mn |
| Sep 30, 2022 | 220.49 Mn |
| Jun 30, 2022 | 233.43 Mn |
| Mar 31, 2022 | 244.56 Mn |
| Dec 31, 2021 | 263.37 Mn |
| Sep 30, 2021 | 168.25 Mn |